ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
CHMP takes negative view on Sarepta’s DMD therapy
pharmatimes
May 07, 2018Sarepta has indicated that there could be a delay to getting its Duchenne muscular dystrophy therapy Exondys approved in Europe, revealing that the European Medicine Agency’s Committee for Medicinal Products for Human Use’s trend vote was negative.
Pharma Sources Insight January 2025
